• Observational Study of Patients Older Than 60 Years With Acute Myeloblastic Leukemia

  NCT01966497

  Unknown statusObservationalUpdated Nov 20, 2017
• Study of Management and Prognosis of Patients With Acute Myeloblastic Leukemia in Saint-Antoine Hospital

  NCT05558943

  Not yet recruitingObservationalUpdated Apr 2, 2025
• Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)

  NCT04777916

  RecruitingObservationalUpdated Oct 3, 2025
• Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia

  NCT02844218

  CompletedObservationalUpdated Jul 26, 2016
• Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

  NCT03226418

  CompletedInterventionalPhase 2Updated Mar 10, 2026
• Program of Evaluation and Geriatric Intervention on the Functional Status, Quality of the Life, and Survival

  NCT01188330

  Unknown statusInterventionalNot ApplicableUpdated Oct 31, 2013

ClinicalTrials.gov ID

NCT06891144

Lead Sponsor

French Innovative Leukemia OrganisationOTHER

Overall Status

Recruiting

Study Type

Observational

Enrollment

1,000Estimated

Last Update Posted

Mar 24, 2025Actual

Start Date

Jan 6, 2015Actual

Primary Completion Date

Jan 6, 2030Estimated

Completion Date

Jan 6, 2031Estimated

Official Title

Epidemiological Study of a Prospective Cohort of Patients Aged 60 and Over Managed for Acute Myeloid Leukemia (AML) and Receiving Intensive Induction Therapy

Brief Summary

This observational epidemiological study targets patients aged 60 and over with de novo or secondary acute myeloblastic leukemia suitable for intensive receive intensive induction therapy as defined by the group. The main aim of the study is to determine the epidemiological characteristics of AML patients, both clinically and biologically, and to correlate these to their outcome. The incidence of AML increases with age, exponentially after the age of 50, giving a median age at diagnosis of close to 70 years, with over half of patients half of patients are over 60 at diagnosis. The principle of treatment as in younger patients, is based on trying to achieve complete remission (CR). remission (CR). Observed complete remission rates range from 38 to 70%. Long-term survival of elderly subjects remains limited, at around 10 to 15%, despite the various types of consolidation tried out in recent years.

years. However, intensive chemotherapy remains the preferred option for initial treatment of these hematological diseases when general condition and comorbidities allow. As shown by Swedish registry studies, it is associated with improved life expectancy.

The proportion of patients who can receive intensive initial treatment is not well known in France, probably varies widely from one region to another, and certainly decreases with increasing age. Only the registry studies currently underway will enable us to assess this precisely.

• AML, Adult

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Patients aged 60 and over
• Patients with previously untreated de novo or secondary AML
• Patients suitable for standard intensive treatment
• Patients who have read the information document and agreed to the collection of data concerning them (signature of informed consent).

Exclusion Criteria:

• Patients with AML 3
• Patients with severe, uncontrolled infection at the time of inclusion
• Patients with psychiatric or social disorders that will prevent compliance with the protocol
• Patients without health insurance (affiliation to a social security scheme)

Observational Model

Cohort

Time Perspective

Cross-Sectional

Lead Sponsor

French Innovative Leukemia OrganisationOTHER

acontejean@ch-annecygenevois.fr

chebrek.safia@ch-avignon.fr

abanos@ch-cotebasque.fr

ydesbrosses@chu-besancon.fr

gaelle.guillerm@chu-brest.fr

bruno.audhuy@ch-colmar.fr

MCarre1@chu-grenoble.fr

pierre.peterlin@chu-nantes.fr

stefan.wickenhauser@chu-nimes.fr

arnaud.pigneux@chu-bordeaux.fr

Maria-Pilar.GALLEGO-HERNANZ@chu-poitiers.fr

chimberlin@chu-reims.fr

tony.marchand@chu-rennes.fr

a.villate@chu-tours.fr